TY  - JOUR
AU  - Sopić, Miron
AU  - Vladimirov, Sandra
AU  - Munjas, Jelena
AU  - Mitić, Tijana
AU  - Hall, Ignacio Fernando
AU  - Jušić, Amela
AU  - Ružić, Dušan
AU  - Devaux, Yvan
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5637
AB  - Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.
PB  - John Wiley and Sons Inc
T2  - British Journal of Pharmacology
T1  - Targeting noncoding RNAs to treat atherosclerosis
DO  - 10.1111/bph.16412
ER  - 

@article{
author = "Sopić, Miron and Vladimirov, Sandra and Munjas, Jelena and Mitić, Tijana and Hall, Ignacio Fernando and Jušić, Amela and Ružić, Dušan and Devaux, Yvan",
year = "2024",
abstract = "Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.",
publisher = "John Wiley and Sons Inc",
journal = "British Journal of Pharmacology",
title = "Targeting noncoding RNAs to treat atherosclerosis",
doi = "10.1111/bph.16412"
}

Sopić, M., Vladimirov, S., Munjas, J., Mitić, T., Hall, I. F., Jušić, A., Ružić, D.,& Devaux, Y.. (2024). Targeting noncoding RNAs to treat atherosclerosis. in British Journal of Pharmacology
John Wiley and Sons Inc..
https://doi.org/10.1111/bph.16412

Sopić M, Vladimirov S, Munjas J, Mitić T, Hall IF, Jušić A, Ružić D, Devaux Y. Targeting noncoding RNAs to treat atherosclerosis. in British Journal of Pharmacology. 2024;.
doi:10.1111/bph.16412 .

Sopić, Miron, Vladimirov, Sandra, Munjas, Jelena, Mitić, Tijana, Hall, Ignacio Fernando, Jušić, Amela, Ružić, Dušan, Devaux, Yvan, "Targeting noncoding RNAs to treat atherosclerosis" in British Journal of Pharmacology (2024),
https://doi.org/10.1111/bph.16412 . .